08:40 AM EDT, 05/13/2024 (MT Newswires) -- Avicanna Inc. ( AVCNF ) , a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, announced Monday completion of the retrospective observational real-world evidence study using its RHO Phyto branded Ultra CBD Topical Cream on patients with epidermolysis bullosa.

A statement noted the retrospective cohort study evaluated the reported and documented responses related to wound healing, pain, and itch end points through images for study purposes to examine and evaluate the effect of RHO Phyto branded Ultra CBD Topical Cream on wound healing. The RHO Phyto branded Ultra CBD Topical Cream is an oil based 3% CBD localized cream developed to target dermatology conditions.

Monday's statement noted the study enrolled 20 patients (14 male patients and 6 female patients) with an average age of 17.3 years with various subtypes of epidermolysis bullosa including dystrophic (60%), simplex (30%) and junctional (10%). After one month of daily application of the 3% CBD Cream, 55% of patient reported improvements in wound healing while 45% displayed wound stability. Evaluation of self-reported itch and pain scores were reported in 65% and 50% of patients, respectively. Of the study participants evaluated, 45% continued to use treatment over 6 months.

Dr. Elena Pope in the statement said, "The use of RHO PhytoTM branded Ultra CBD Topical Cream is a novel topical therapeutic option for EB patients, providing symptom relief and potentially aiding in wound healing with good tolerability. Further prospective studies are needed to substantiate these findings."